Schlienger Raymond G, Jick Susan S, Meier Christoph R
Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacology and Toxicology, University Hospital, Petersgraben 4, CH-4031 Basel, Switzerland.
Pediatrics. 2004 Aug;114(2):469-73. doi: 10.1542/peds.114.2.469.
To determine whether children or adolescents who are exposed to inhaled corticosteroids (ie, beclomethasone, budesonide, fluticasone) are at a higher risk of having bone fractures compared with nonexposed individuals.
We performed a population-based nested case-control analysis using data from the United Kingdom-based General Practice Research Database. Within a base population of 273,456 individuals aged 5 to 79 years, we identified by International Classification of Diseases codes children or adolescents who were aged 5 to 17 years with a fracture diagnosis and up to 6 control subjects per case matched to cases on age, gender, general practice attended, calendar time, and years of history in the GPRD. We compared use of inhaled steroids before the index date between fracture cases and control patients.
We identified 3744 cases and 21,757 matched control subjects aged 5 to 17 years. Current exposure to inhaled steroids did not reveal a substantially altered fracture risk compared with nonusers, even in individuals with current longer term exposure (ie, > or =20 prescriptions; adjusted odds ratio 1.15; 95% confidence interval: 0.89-1.48). In individuals with current or previous exposure to oral steroids, the adjusted odds ratio for current long-term inhaled steroid use compared with nonusers was 1.21 (95% confidence interval: 0.99-1.49).
Exposure to inhaled steroids does not materially increase the fracture risk in children or adolescents compared with nonexposed individuals.
确定与未接触吸入性糖皮质激素(即倍氯米松、布地奈德、氟替卡松)的儿童或青少年相比,接触这些药物的儿童或青少年发生骨折的风险是否更高。
我们使用来自英国全科医学研究数据库的数据进行了一项基于人群的巢式病例对照分析。在273456名年龄在5至79岁的基础人群中,我们通过国际疾病分类编码确定了年龄在5至17岁且有骨折诊断的儿童或青少年,每个病例最多匹配6名对照,对照在年龄、性别、就诊的全科诊所、日历时间以及在全科医学研究数据库中的病史等方面与病例相匹配。我们比较了骨折病例和对照患者在索引日期之前吸入性类固醇的使用情况。
我们确定了3744例年龄在5至17岁的病例和21757名匹配的对照。与未使用者相比,当前接触吸入性类固醇并未显示骨折风险有实质性改变,即使是在当前长期接触(即≥20次处方)的个体中也是如此(调整后的优势比为1.15;95%置信区间:0.89 - 1.48)。在当前或既往接触口服类固醇的个体中,当前长期使用吸入性类固醇与未使用者相比的调整后优势比为1.21(95%置信区间:0.99 - 1.49)。
与未接触的个体相比,接触吸入性类固醇并不会实质性增加儿童或青少年的骨折风险。